Scalper1 News
For a biotech startup, getting a product approved is the main hurdle. But then the company faces another one: getting paid. That’s where Exact Sciences (EXAS) finds itself. On Aug. 11, the FDA approved Cologuard, an innovative, noninvasive DNA screening test for colon cancer. Since doctors recommend colon screening for people over 50, Medicare figures to be a major payer for Cologuard. Exact Sciences is still waiting for the Center for Medicare & Scalper1 News
Scalper1 News